 |
 |
 |
| |
De: PR Newswire
Brasil
Para: THERESA CATHARINA DE GÓES CAMPOS
Assunto: Innovative Technology for Treatment of
Renal Anaemia Unveiled Today
16 de junho de 2006 08:07 HORALOCAL
Innovative Technology for Treatment of Renal
Anaemia Unveiled Today
- First Human Cell Line-Derived Erythropoietin
Research Reported
- Abstract Numbers: 562 and 576
BASINGSTOKE, England, June 16 /PRNewswire/ --
Effective treatment of
anaemia in patients suffering from chronic
kidney disease (CKD)(i) is
possible with the first erythropoietin product
produced in a human
cell line.(1)
DYNEPO(R) (epoetin delta), developed using
innovative gene activation
technology in a human cell line, corrects and
maintains haemoglobin
levels in patients suffering from anaemia and
CKD who are on
dialysis, according to the results of a study
presented for the first
time today at the 11th Congress of the European
Hematology
Association (EHA).(1) A second study, also
presented for the first
time today, highlighted a key difference between
DYNEPO and other
erythropoietin treatments - na unquantifiably
low amount of a
specific carbohydrate residue compared to those
treatments produced in
Chinese Hamster Ovary cell lines. This
carbohydrate residue is known
to produce immune responses in humans.(2,3)
Potential differences in
immunogenicity between DYNEPO and other
erythropoietin treatments
have not been investigated in clinical practice.
Dr Iain MacDougall, Consultant Nephrologist and
Honorary Senior
Lecturer from the Renal Unit in King's College
Hospital, London
commented, "There is a pressing need for further
research into the
differences between DYNEPO and conventional
erythropoietin treatments
that are not produced in human cell lines. It
will be fascinating to
see whether these differences will ultimately
translate into specific
benefits for patients with CKD who are suffering
from anaemia." By
stimulating red blood cell production in the
bone marrow, DYNEPO
performs the same role as naturally occurring
human erythropoietin.
The prevalence of anaemia in patients with CKD
rises as kidney
function Declines(4) and in Europe, the
prevalence of end stage renal
disease is estimated at 225,000, growing at 6
per cent per annum,
with more than 80 per cent of these patients on
dialysis.(5)
Dr Raymond Pratt, Vice President Global Medical
Affairs, Shire,
added, "Shire is proud to be involved in
products produced by this
ground-breaking gene activation technology. We
are committed to
bringing innovative products, like DYNEPO, to
market to meet
patients' needs. DYNEPO will be another addition
to our renal
therapeutics area, focusing on patients with
anaemia and CKD."
The primary cause of anaemia in CKD is a
deficiency in
erythropoietin, a protein produced by the
kidneys responsible for red
blood cell production.(6) As renal function
declines, so does the
capacity for producing erythropoietin and
consequently red blood
cells. Additionally, anaemia in patients with
CKD may be aggravated
by a loss of red blood cells during
haemodialysis. Consequences can be
serious with increased risk of cardiovascular
disease, the main cause
of death amongst dialysis patients, along with a
major impact on the
quality of life through fatigue and a reduction
in life-expectancy
due to cardiovascular complications.
ABOUT DYNEPO
If the kidney starts to fail, patients require
an increase in
erythropoietin from a treatment such as DYNEPO
in order to increase
red blood cell production. Red blood cells (erythrocytes)
contain
haemoglobin and are vital for oxygen
transportation around the body.
Erythropoietin is produced in the kidneys and
stimulates the bone
marrow to produce more red blood cells by
promoting the development
of stem cells into mature red blood cells. These
cells are then
released into the blood stream. DYNEPO works in
exactly the same way.
Notes to Editors:
Shire Plc
Shire's strategic goal is to become the leading
specialty
pharmaceutical company that focuses on meeting
the needs of the
specialist physician. Shire (LSE: SHP, Nasdaq:
SHPGY, TSX: SHQ),
focuses its business on central nervous system,
gastrointestinal,
general products with an emphasis on renal, and
human genetic
therapies -- all being areas in which Shire has
a commercial
presence. The structure is sufficiently flexible
to allow Shire to
target new therapeutic areas to the extent
opportunities arise
through acquisitions. Shire believes that a
carefully selected
portfolio of products with strategically aligned
and relatively
small-scale sales forces will deliver strong
results. Shire's
strategy is to develop and market products for
specialty physicians.
Shire's in-licensing and merger and acquisition
efforts are focused
on products in niche markets with strong
intellectual property
protection either in the US or Europe. For
further information on
Shire, please visit the Company's website:
www.shire.com .
References
1. R Pratt. Epoetin delta, erythropoietin
produced by a human cell
line, is effective in the treatment of renal
anaemia. Poster
presented at 11th Congress of European
Hematology, 15-18 June,
Amsterdam, Holland, 2006, organized by the
European Hematology
Association (EHA).
2. Varki A. Loss of N-glycolylneuraminic acid in
humans: Mechanisms,
consequences, and implications for hominid
evolution. Yrbk Phys
Anthropol 2001; 44: 54-69.
3. Z Shahrokh, S Flatman, M Davies, A Baycroft,
M Heartlein.
Erythropoietin produced by a human cell line has
only trace levels of
potentially immunogenic N-glycolylneuraminic
acid residues. Poster
presented at 11th Congress of European
Hematology, 15-18 June 2006,
Amsterdam, Holland, organized by the European
Hematology Association
(EHA).
4. Locatelli F, Alijama P, Barany P et al.
Revised European Best
Practice Guidelines for the management of
anaemia in patients with
chronic renal failure. Section 1: Anaemia
evaluation. Nephrol Dial
Transplant 2004a; 19 Suppl 2: ii2-ii5.
5. Molowa DT. First annual nephrology survey.
With a focus on Aranesp
and Renagel. J.P.Morgan Securities Inc. Equity
Research. 13 February
2002.
6. Eschbach JW. Current concepts of anemia
management in chronic
renal failure: impact of NKF-DOQI. Semin Nephrol
2000; 24(4): 320-329.
(i) CKD is sometimes referred to as chronic
renal failure (CRF).
SOURCE Shire Plc
06/16/2006
CONTACT: Media Shire, Jessica Mann,
+44-1256-894-280; Media PR agents
for Resolute Communications, +44-7921-489-607,
DYNEPO, Dr Diane Ross;
Media PR agents for Resolute Communications,
DYNEPO, Lizzy Ray,
+44-20-7357-8187
Web site: http://www.shire.com
(SHPGY)
BNED: NG
FONTE: PR NEWSWIRE LATIN AMERICA
CORAL GABLES - MIAMI-US
CONTATOS: USA-MARY D'LEON
BRASIL-NÉLIA GARCIA
TELS: USA:1-305-507-2550/BRASIL:55-21-2132-8461
FAXES: USA:1-305-461-8670/BRASIL:55-21-2132-8469
E-MAILS: nelia_garcia@prnewswire.com.br
mary_dleon@prnewswire.com
PALAVRA-CHAVE: RJ
PALAVRA-CHAVE/RAMO DE ATIVIDADE: INDÚSTRIA
FARMACÊUTICA
PALAVRA-CHAVE/EMPRESA: SHIRE PLC
O texto acima, distribuído pela PR Newswire
Brasil, é de inteira responsabilidade de seu
cliente. A utilização deste material não implica
em custo.
|
|
|
|
